Literature DB >> 29955845

Predictors of Renal Function and Calcifications in Primary Hyperparathyroidism: A Nested Case-Control Study.

Henriette Ejlsmark-Svensson1,2, Lise Sofie Bislev1,2, Lars Rolighed3, Tanja Sikjaer1,2, Lars Rejnmark1,2.   

Abstract

Context: Some patients with primary hyperparathyroidism (PHPT) develop renal calcifications. Investigation of urinary and nonurinary risk factors are essential. Objective: We aimed to study the prevalence and potential biochemical predictors of renal calcifications. Design: Nested case-control study. Setting: University hospital. Participants: We identified 792 patients with PHPT from 2005 to 2015. We used biochemical data to validate the diagnosis of PHPT. Main Outcome Measures: The prevalence of renal calcifications defined as nephrolithiasis or nephrocalcinosis assessed by a routine CT scan at the time of diagnosis.
Results: A total of 792 patients with PHPT were identified among whom 617 patients (78%) had a CT scan preformed. We found a prevalence of renal calcifications of 23%, equally frequent between sexes. A total of 76 patients (12%) had nephrolithiasis and 75 patients (12%) had nephrocalcinosis where 7 patients (1%) had both nephrolithiasis and nephrocalcinosis. Compared with patients without renal calcifications, patients with renal calcifications had significantly higher levels of ionized calcium, parathyroid hormone, and 24-hour calcium excretion (Pall < 0.01). Patients with nephrocalcinosis had higher plasma levels of phosphate and a higher calcium-phosphate product compared with patients with nephrolithiasis (Pall < 0.05). Impaired renal function (estimated glomerular filtration rate <60 mL/min) was observed in 12% of patients. However, no differences in renal function were observed between those with and without renal calcifications.
Conclusion: Renal calcifications are frequent in patients with PHPT and are associated with the severity of the disease. Impaired renal function is also common in PHPT, but renal function was not associated with renal calcifications.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29955845     DOI: 10.1210/jc.2018-00923

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

1.  Hypercalciuria: its value as a predictive risk factor for nephrolithiasis in asymptomatic primary hyperparathyroidism?

Authors:  F Saponaro; F Cetani; L Mazoni; M Apicella; M Di Giulio; F Carlucci; M Scalese; E Pardi; S Borsari; J P Bilezikian; C Marcocci
Journal:  J Endocrinol Invest       Date:  2019-12-23       Impact factor: 4.256

Review 2.  [Asymptomatic primary hyperparathyroidism : Operation or observation?]

Authors:  Katja Gollisch; Heide Siggelkow
Journal:  Internist (Berl)       Date:  2021-03-12       Impact factor: 0.743

Review 3.  MANAGEMENT OF ENDOCRINE DISEASE: Unmet therapeutic, educational and scientific needs in parathyroid disorders.

Authors:  Jens Bollerslev; Camilla Schalin-Jäntti; Lars Rejnmark; Heide Siggelkow; Hans Morreau; Rajesh Thakker; Antonio Sitges-Serra; Filomena Cetani; Claudio Marcocci
Journal:  Eur J Endocrinol       Date:  2019-06-01       Impact factor: 6.664

4.  Bone Turnover Markers in Response to Ultrasound-Guided Microwave Ablation for Primary Hyperparathyroidism.

Authors:  Wenjing Ni; Yue Yuan; Xiaoqiu Chu; Guofang Chen; Xue Han; Jie Li; Xinping Wu; Jianhua Wang; Chao Liu; Shuhang Xu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-01       Impact factor: 5.555

5.  Occult Renal Calcifications in Patients with Normocalcemic Primary Hyperparathyroidism and Their Association with the Parathyroid Hormone-Vitamin D Axis.

Authors:  Fernanda Victor; Alyne Layane Pereira Lemos; Anna Mirella de Holanda Ribas; Leonardo Bandeira; José Henrique Pimentel; Luiz Otávio de Andrade Damázio; Francisco Bandeira
Journal:  Int J Endocrinol       Date:  2022-04-08       Impact factor: 2.803

6.  Risk factors and implications associated with renal mineralization in chronic kidney disease in cats.

Authors:  Pak-Kan Tang; Rosanne E Jepson; Yu-Mei Chang; Rebecca F Geddes; Mark Hopkinson; Jonathan Elliott
Journal:  J Vet Intern Med       Date:  2022-01-19       Impact factor: 3.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.